Zulfiqar Malik, PhD
Hematology & Oncology · Marietta, GANPI 1841364908
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,450 of the $8,055 with a category attached, or 80.1%. 32 manufacturers reported payments, led by Amgen at 44.3% of the total. Reporting peaked in 2020 at $3,585 and has fallen 81.4% since, to $666 in 2025.
Across 81 payments — averaging $99.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Ipsen Biopharmaceuticals, Inc$3K
- Pfizer$222
- Novartis$183
- AstraZeneca$144
- Bristol Myers Squibb$138
- plus $917 from 26 others
Across 107 payments — averaging $7627.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$236K
- Merck$196K
- Genentech, Inc.$99K
- Seagen Inc.$90K
- AstraZeneca$28K
- Gilead$25K
- plus $142K from 12 others
What the payments were for
- Consulting fees$6,45080%
- Food & beverage$1,59320%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $3,570 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,880 |
| Pfizer | 11 | $222 |
| Novartis | 9 | $183 |
| AstraZeneca | 6 | $144 |
| Bristol Myers Squibb | 8 | $138 |
| Gilead(2 entities) | 7 | $117 |
| AbbVie | 4 | $87 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Pharmaessentia USA Corporation | 3 | $66 |
| Astellas Pharma US Inc | 3 | $65 |
| Sanofi | 2 | $46 |
| Eisai Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Adaptive Biotechnologies Corporation | 2 | $40 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $34 |
| Coherus Oncology, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Merck | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Exelixis Inc. | 1 | $20 |
| Seagen Inc. | 1 | $20 |
| Nuvation Bio Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $18 |
| GSK | 1 | $17 |
| Mylan Institutional Inc. | 1 | $15 |
| Sobi, Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONIVYDE$2,880
How this compares
$8,055 in reported general payments places this provider in the 60th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 33 | $517,537 |
| BrukinsaZanubrutinib | 34 | $380,440 |
| ErleadaApalutamide | 16 | $222,281 |
| EliquisApixaban | 139 | $125,511 |
| XareltoRivaroxaban | 55 | $50,335 |
| Hydroxyurea | 56 | $1,483 |
| Oxycodone Hcl | 34 | $1,407 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $780 |
| ValacyclovirValacyclovir Hcl | 25 | $552 |
| Ondansetron Hcl | 57 | $536 |
| Prochlorperazine Maleate | 49 | $524 |
| Olanzapine | 33 | $434 |
| Morphine Sulfate ErMorphine Sulfate | 16 | $431 |
| Dexamethasone | 26 | $333 |
| Letrozole | 11 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $138 | $517,53733 claims |
| Johnson & JohnsonErleada, Xarelto | $13 | $272,61671 claims |
| PfizerEliquis | $222 | $125,511139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Marietta
- Steven McCuneMarietta$450K
- Gena Volas ReddMarietta$77K
- John FrenchMarietta$70K
- Dean KirkelMarietta$44K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.